Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant

被引:93
作者
Basse, Nicolas [1 ]
Kaar, Joel L. [1 ]
Settanni, Giovanni [1 ]
Joerger, Andreas C. [1 ]
Rutherford, Trevor J. [1 ]
Fersht, Alan R. [1 ]
机构
[1] MRC, Ctr Prot Engn, Cambridge CB2 0QH, England
来源
CHEMISTRY & BIOLOGY | 2010年 / 17卷 / 01期
基金
英国医学研究理事会;
关键词
P53 CORE DOMAIN; TUMOR-SUPPRESSOR P53; MOLECULAR-DYNAMICS SIMULATIONS; DNA-BINDING; ORGANIC-SOLVENTS; STRUCTURAL BASIS; LIGAND-BINDING; LEAD DISCOVERY; WILD-TYPE; PROTEIN;
D O I
10.1016/j.chembiol.2009.12.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p53 cancer mutation Y220C induces formation of a cavity on the protein's surface that can accommodate stabilizing small molecules. We combined fragment screening and molecular dynamics to assess the druggability of p53-Y220C and map ligand interaction sites within the mutational cavity. Elucidation of the binding mode of fragment hits by crystallography yielded a clear picture of how a drug might dock in the cavity. Simulations that solvate the protein with isopropanol found additional sites that extend the druggable surface. Moreover, structural observations and simulation revealed the dynamic landscape of the cavity, which improves our understanding of the impact of the mutation on p53 stability. This underpins the importance of considering flexibility of the cavity in screening for optimized ligands. Our findings provide a blueprint for the design of effective drugs that rescue p53-Y220C.
引用
收藏
页码:46 / 56
页数:11
相关论文
共 57 条
[1]   PHENIX:: building new software for automated crystallographic structure determination [J].
Adams, PD ;
Grosse-Kunstleve, RW ;
Hung, LW ;
Ioerger, TR ;
McCoy, AJ ;
Moriarty, NW ;
Read, RJ ;
Sacchettini, JC ;
Sauter, NK ;
Terwilliger, TC .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 :1948-1954
[2]  
[Anonymous], 1992, THESIS TU MUNCHEN MU
[3]   Collective motions in HIV-1 reverse transcriptase: Examination of flexibility and enzyme function [J].
Bahar, I ;
Erman, B ;
Jernigan, RL ;
Atilgan, AR ;
Covell, DG .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 285 (03) :1023-1037
[4]   Correlation between native-state hydrogen exchange and cooperative residue fluctuations from a simple model [J].
Bahar, I ;
Wallqvist, A ;
Covell, DG ;
Jernigan, RL .
BIOCHEMISTRY, 1998, 37 (04) :1067-1075
[5]   Direct evaluation of thermal fluctuations in proteins using a single-parameter harmonic potential [J].
Bahar, I ;
Atilgan, AR ;
Erman, B .
FOLDING & DESIGN, 1997, 2 (03) :173-181
[6]   Ligand efficiency and fragment-based drug discovery [J].
Bembenek, Scott D. ;
Tounge, Brett A. ;
Reynolds, Chades H. .
DRUG DISCOVERY TODAY, 2009, 14 (5-6) :278-283
[7]   Targeted rescue of a destabilized mutant of p53 by an in silico screened drug [J].
Boeckler, Frank M. ;
Joerger, Andreas C. ;
Jaggi, Gaurav ;
Rutherford, Trevor J. ;
Veprintsev, Dmitry B. ;
Fersht, Alan R. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (30) :10360-10365
[8]   Fluorine in medicinal chemistry [J].
Böhm, HJ ;
Banner, D ;
Bendels, S ;
Kansy, M ;
Kuhn, B ;
Müller, K ;
Obst-Sander, U ;
Stahl, M .
CHEMBIOCHEM, 2004, 5 (05) :637-643
[9]   CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217
[10]   Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy [J].
Bullock, AN ;
Henckel, J ;
Fersht, AR .
ONCOGENE, 2000, 19 (10) :1245-1256